NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
- PMID: 22570745
- PMCID: PMC3343154
- DOI: 10.5009/gnl.2012.6.2.149
NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Abstract
While non-alcoholic fatty liver disease (NAFLD) is highly prevalent (15% to 45%) in modern societies, only 10% to 25% of cases develop hepatic fibrosis leading to cirrhosis, end-stage liver disease or hepatocellular carcinoma. Apart from pre-existing fibrosis, the strongest predictor of fibrotic progression in NAFLD is steatohepatitis or non-alcoholic steatohepatitis (NASH). The critical features other than steatosis are hepatocellular degeneration (ballooning, Mallory hyaline) and mixed inflammatory cell infiltration. While much is understood about the relationship of steatosis to metabolic factors (over-nutrition, insulin resistance, hyperglycemia, metabolic syndrome, hypoadiponectinemia), less is known about inflammatory recruitment, despite its importance for the perpetuation of liver injury and fibrogenesis. In this review, we present evidence that liver inflammation has prognostic significance in NAFLD. We then consider the origins and components of liver inflammation in NASH. Hepatocytes injured by toxic lipid molecules (lipotoxicity) play a central role in the recruitment of innate immunity involving Toll-like receptors (TLRs), Kupffer cells (KCs), lymphocytes and neutrophils and possibly inflammasome. The key pro-inflammatory signaling pathways in NASH are nuclear factor-kappa B (NF-κB) and c-Jun N-terminal kinase (JNK). The downstream effectors include adhesion molecules, chemokines, cytokines and the activation of cell death pathways leading to apoptosis. The upstream activators of NF-κB and JNK are more contentious and may depend on the experimental model used. TLRs are strong contenders. It remains possible that inflammation in NASH originates outside the liver and in the gut microbiota that prime KC/TLR responses, inflamed adipose tissue and circulating inflammatory cells. We briefly review these mechanistic considerations and project their implications for the effective treatment of NASH.
Keywords: Hepatic fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures
Similar articles
-
Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.Adv Exp Med Biol. 2018;1061:19-44. doi: 10.1007/978-981-10-8684-7_3. Adv Exp Med Biol. 2018. PMID: 29956204 Review.
-
Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.J Gastroenterol Hepatol. 2012 Feb;27(2):341-50. doi: 10.1111/j.1440-1746.2011.06939.x. J Gastroenterol Hepatol. 2012. PMID: 21929649
-
Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.J Biol Chem. 2018 Jun 1;293(22):8656-8671. doi: 10.1074/jbc.RA117.001653. Epub 2018 Apr 17. J Biol Chem. 2018. PMID: 29666185 Free PMC article.
-
Decoding cell death signals in liver inflammation.J Hepatol. 2013 Sep;59(3):583-94. doi: 10.1016/j.jhep.2013.03.033. Epub 2013 Apr 6. J Hepatol. 2013. PMID: 23567086 Review.
-
Understanding the cellular interactome of non-alcoholic fatty liver disease.JHEP Rep. 2022 Jun 15;4(8):100524. doi: 10.1016/j.jhepr.2022.100524. eCollection 2022 Aug. JHEP Rep. 2022. PMID: 35845296 Free PMC article. Review.
Cited by
-
Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists.Cardiovasc Endocrinol Metab. 2020 Mar 23;9(3):96-100. doi: 10.1097/XCE.0000000000000197. eCollection 2020 Sep. Cardiovasc Endocrinol Metab. 2020. PMID: 32803141 Free PMC article. Review.
-
The metabolomic window into hepatobiliary disease.J Hepatol. 2013 Oct;59(4):842-58. doi: 10.1016/j.jhep.2013.05.030. Epub 2013 May 25. J Hepatol. 2013. PMID: 23714158 Free PMC article. Review.
-
Agaricus brasiliensis KA21 May Prevent Diet-Induced Nash Through Its Antioxidant, Anti-Inflammatory, and Anti-Fibrotic Activities in the Liver.Foods. 2019 Nov 4;8(11):546. doi: 10.3390/foods8110546. Foods. 2019. PMID: 31689883 Free PMC article.
-
CXCR3 Inhibition Blocks the NF-κB Signaling Pathway by Elevating Autophagy to Ameliorate Lipopolysaccharide-Induced Intestinal Dysfunction in Mice.Cells. 2023 Jan 1;12(1):182. doi: 10.3390/cells12010182. Cells. 2023. PMID: 36611975 Free PMC article.
-
Dietary Green Tea Extract Prior to Spinal Cord Injury Prevents Hepatic Iron Overload but Does Not Improve Chronic Hepatic and Spinal Cord Pathology in Rats.J Neurotrauma. 2018 Dec 15;35(24):2872-2882. doi: 10.1089/neu.2018.5771. Epub 2018 Sep 27. J Neurotrauma. 2018. PMID: 30084733 Free PMC article.
References
-
- Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 2007;22:788–793. - PubMed
-
- Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99–S112. - PubMed
-
- Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol. 2010;25:672–690. - PubMed
-
- Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011;26(Suppl 1):163–172. - PubMed
-
- Wong VW, Chu WC, Wong GL, et al. Prevalence of nonalcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61:409–415. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous